alexa Lack Of Full Re-constitution Of Exhausted HCV-specific CD8+ T Cells Following IFN-free DAA Therapy Is Partially Reversed Upon Immune Check-point Inhibitions During Chronic HCV
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

8th European Immunology Conference
June 29-July 01, 2017 Madrid, Spain

Amare Aregay, Solomon Owusu Sekyere, Marcus Cornberg and Heiner Wedemeyer
Hannover Medical School, Germany
Posters & Accepted Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899-C1-037
Hepatitis C virus (HCV) persists and sets-up chronicity in majority of infected patients. Fortunately, new IFN-free direct-acting antiviral (DAA) therapies resulted in rapid and sustained clearance of HCV from infected patients. However, the impact of HCV clearance on HCV-specific CD8+ T cell responses remain yet to be understood. Owing to the rapid cessation of HCV replication and ensuing abrupt clearance of viral antigens mediated by IFN-free DAAs, we aimed at investigating the possible repercussions thereof on exhausted HCV-specific CD8+ T cells during chronic hepatitis C. We could show, by employing multimer-based magnetic bead enrichment technique that unlike activation markers that increased, ex-vivo surface expressions of co-regulatory markers remain unaffected following HCV clearance. Upon 10 day peptide stimulation in-vitro, the overall frequency of dextramer positive CD8+ T cells increased from baseline to 24 weeks after treatment in patients without advanced liver disease despite the fact that majority (55%) of patients did not show increase in proliferation. Meanwhile, HCV-specific CD8+ T cells proliferative capacity was not restored in patients with advanced liver disease. In addition, cytokines secretion and degranulation of HCV-specific CD8+ T cells remain unaffected following HCV clearance. Importantly, however, blockade of PDL1 pathway as well as PDL1/TIM3 double blockade resulted in enhanced proliferation and cytokine secretion by HCV-specific CD8+ T cells after IFN-free DAA therapy. Interestingly, HCV-specific CD8+ T cells that did not show increase in proliferation upon peptide stimulation alone could preferentially increase their proliferation and cytokine secretion upon blockade of PDL1 pathway. Taken together, our data implies that despite rapid HCV clearance, IFN-free DAA therapy does not fully re-constitute the altered phenotype and function of HCV-specific CD8+ T cells in chronic HCV. However, combining PDL1 or PDL1/TIM3 blocking therapy with IFN-free DAA therapy might possibly confer a functional and protective virus-specific CD8+ T cell response against re-infection.

Amare Aregay is currently pursuing his PhD at the Department of Gasteroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany under supervision of Professor Dr. Heiner Wedemeyer. He completed his Master’s degree from Wageningen University Research Center. His current PhD work focuses on Cellular Immune Response (specifically T and NK cell response) towards chronic HCV infection in the context of IFN-free DAA therapy and liver transplantation.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version